VENCLEXTA is a chemo-free option that gives adults with chronic lymphocytic leukemia (CLL) the chance for a treatment-free period.
The audience.
HCPs treating adults with CLL (and AML) as well as patients.
The challenge.
There wasn’t campaign imagery to coincide with the launch of the CLL indication so we needed a strong headline to do the heavy lifting.
The ask.
Create launch materials for the additional CLL indication to inform HCPs as well as patients.
THE STRENGTH TO STOP
VEN offers unparalleled deep and durable responses, a manageable safety profile, and the opportunity for a treatment-free period.
Core sales aid for CLL indication launch
